Show simple item record

dc.contributor.authorAlegría-Arcos, Melissa
dc.contributor.authorBarbosa, Tábata
dc.contributor.authorSepúlveda, Felipe
dc.contributor.authorCombariza, German
dc.contributor.authorGonzález, Janneth
dc.contributor.authorGil, Carmen
dc.contributor.authorMartínez, Ana
dc.contributor.authorRamírez, David
dc.date.accessioned2024-04-10T05:43:06Z
dc.date.available2024-04-10T05:43:06Z
dc.date.issued2022
dc.identifier10.3389/fphar.2022.952192
dc.identifier.issn16639812
dc.identifier.urihttps://hdl.handle.net/20.500.12728/10793
dc.description.abstractThe coronavirus disease 2019 pandemic accelerated drug/vaccine development processes, integrating scientists all over the globe to create therapeutic alternatives against this virus. In this work, we have collected information regarding proteins from SARS-CoV-2 and humans and how these proteins interact. We have also collected information from public databases on protein–drug interactions. We represent this data as networks that allow us to gain insights into protein–protein interactions between both organisms. With the collected data, we have obtained statistical metrics of the networks. This data analysis has allowed us to find relevant information on which proteins and drugs are the most relevant from the network pharmacology perspective. This method not only allows us to focus on viral proteins as the main targets for COVID-19 but also reveals that some human proteins could be also important in drug repurposing campaigns. As a result of the analysis of the SARS-CoV-2–human interactome, we have identified some old drugs, such as disulfiram, auranofin, gefitinib, suloctidil, and bromhexine as potential therapies for the treatment of COVID-19 deciphering their potential complex mechanism of action. Copyright © 2022 Alegría-Arcos, Barbosa, Sepúlveda, Combariza, González, Gil, Martínez and Ramírez.es_ES
dc.description.sponsorshipEuropean Commission, EC, (EU 2020/2094); Fondo Nacional de Desarrollo Científico y Tecnológico, FONDECYT, (1220656); Consejo Superior de Investigaciones Científicas, CSIC; Agencia Nacional de Investigación y Desarrollo, ANID, (ACT210012, COVID0199, REDES190074)es_ES
dc.language.isoenes_ES
dc.publisherFrontiers Media S.A.es_ES
dc.subjectCOVID-19es_ES
dc.subjectdrug repurposinges_ES
dc.subjectnetwork pharmacologyes_ES
dc.subjectpolypharmacologyes_ES
dc.subjectprotein–drug interaction networkes_ES
dc.subjectprotein–protein interaction networkes_ES
dc.subjectSARS-CoV-2es_ES
dc.titleNetwork pharmacology reveals multitarget mechanism of action of drugs to be repurposed for COVID-19es_ES
dc.typeArticlees_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record